Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, LIFECORE BIOMEDICAL, INC. reported revenue of $129M, up 0.5% year over year. Operating margin was -13.4% and net margin -30.0%, on a free-cash-flow margin of -10.6% with capital expenditure at 10.4% of revenue. Every figure is computed directly from LFCR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $129M | -13.4% | -30.0% |
| FY2024 | $128M | -6.9% | 9.4% |
| FY2023 | $103M | -21.1% | -96.4% |
| FY2022 | $111M | -10.6% | -104.9% |
| FY2021 | $101M | -8.7% | -32.0% |
How does LFCR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.